Next Article in Journal / Special Issue
Development of Solid Lipid Nanoparticles for Controlled Amiodarone Delivery
Previous Article in Journal
Allergens and Other Harmful Substances in Hydroalcoholic Gels: Compliance with Current Regulation
Previous Article in Special Issue
Improving 2-Chlorotrityl Chloride (2-CTC) Resin Activation
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Novel and Quantitative Detection Assay (effluxR) for Identifying Efflux-Associated Resistance Genes Using Multiplex Digital PCR in Clinical Isolates of Pseudomonas aeruginosa

by
Nontaporn Rattanachak
1,
Sattaporn Weawsiangsang
1,
Robert A. Baldock
2,
Theerasak Jaifoo
3,
Touchkanin Jongjitvimol
4,* and
Jirapas Jongjitwimol
5,6,*
1
Biomedical Sciences Program, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand
2
School of Pharmacy and Biomedical Sciences, Faculty of Science and Health, University of Portsmouth, Portsmouth PO1 2DT, UK
3
Master of Science Program in Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand
4
Biology Program, Faculty of Science and Technology, Pibulsongkram Rajabhat University, Phitsanulok 65000, Thailand
5
Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok 65000, Thailand
6
Centre of Excellence in Biomaterials, Faculty of Science, Naresuan University, Phitsanulok 65000, Thailand
*
Authors to whom correspondence should be addressed.
Methods Protoc. 2023, 6(5), 96; https://doi.org/10.3390/mps6050096
Submission received: 21 August 2023 / Revised: 26 September 2023 / Accepted: 5 October 2023 / Published: 8 October 2023
(This article belongs to the Special Issue Feature Papers in Methods and Protocols 2023)

Abstract

:
The rise of multidrug resistance of Pseudomonas aeruginosa highlights an increased need for selective and precise antimicrobial treatment. Drug efflux pumps are one of the major mechanisms of antimicrobial resistance found in many bacteria, including P. aeruginosa. Detection of efflux genes using a polymerase chain reaction (PCR)-based system would enable resistance detection and aid clinical decision making. Therefore, we aimed to develop and optimize a novel method herein referred to as “effluxR detection assay” using multiplex digital PCR (mdPCR) for detection of mex efflux pump genes in P. aeruginosa strains. The annealing/extension temperatures and gDNA concentrations were optimized to amplify mexB, mexD, and mexY using the multiplex quantitative PCR (mqPCR) system. We established the optimal mqPCR conditions for the assay (Ta of 59 °C with gDNA concentrations at or above 0.5 ng/µL). Using these conditions, we were able to successfully detect the presence of these genes in a quantity-dependent manner. The limit of detection for mex genes using the effluxR detection assay with mdPCR was 0.001 ng/µL (7.04–34.81 copies/µL). Moreover, using blind sample testing, we show that effluxR detection assay had 100% sensitivity and specificity for detecting mex genes in P. aeruginosa. In conclusion, the effluxR detection assay, using mdPCR, is able to identify the presence of multiple mex genes in P. aeruginosa that may aid clinical laboratory decisions and further epidemiological studies.

1. Introduction

Pseudomonas aeruginosa is a Gram-negative bacteria which is recognized as an opportunistic pathogen, causing community and nosocomial infections with a high mortality rate [1,2,3]. The mortality rate from nosocomial pneumonia caused by P. aeruginosa is estimated to be around 70% [4]. Mortality arising from septicemia with P. aeruginosa has been estimated at between 30–50% [5]. Moreover, P. aeruginosa is highly adaptable to environmental changes, due, in part, to its large genome size (5.5–7.0 million base pairs), which encodes a significant number of enzymes regulating metabolism, transportation, and organic compound efflux [6,7]. These mechanisms enable P. aeruginosa to survive in a wide range of environments and spread worldwide [6,7]. Furthermore, these mechanisms permit the resistance of P. aeruginosa to various antimicrobial agents, thereby contributing to the development of multidrug resistance (MDR) [8,9,10,11]. MDR in P. aeruginosa is challenging to treat and results in patient mortality rates of about 15–30% in some regions [12,13,14]. P. aeruginosa is one of three bacterial species which presents a significant health concern worldwide [15,16]. A rapid diagnostic method for identifying drug-resistant P. aeruginosa infections is essential to reduce inappropriate antimicrobial use and, by enabling the selection of the most appropriate treatment initially, reducing mortality rates [17].
A mechanism used by P. aeruginosa to confer antibiotic resistance is efflux pumps, which transport antibiotics or compounds through the outer membrane and out of the cell [18]. The resistance-nodulation-division (RND) efflux pump mechanism of P. aeruginosa is known to enable multidrug resistance [19]. At least three crucial RND pumps, namely the MexAB-OprM, MexCD-OprJ, and MexXY-OprA systems, contribute significantly to antibiotic resistance [18,20,21]. Commonly, the RND pump forms a tripartite complex, involving the outer membrane (via OprM, OprJ, or OprA), the inner membrane (via MexB, MexD, MexF, or MexY), and the periplasmic space components (MexA, MexC, and MexX). Antibiotics or compounds are pumped out of the cell via the coordinated action of the three protein components [22]. An outer membrane protein facilitates the transfer of the substrate through the outer membrane. The inner membrane portion is responsible for substrate specificity and also facilitates pH-related drug transport. The periplasmic space fusion protein bridges the inner and outer membrane proteins [23]. The actions of many antibiotic classes, such as β-lactams, aminoglycosides, fluoroquinolones, tigecycline, cephalosporins, chloramphenicol, and tetracyclines, are negated through the activity of RND pumps [22,24,25].
A polymerase chain reaction (PCR)-based system can be used to detect genes associated with antibiotic resistance [26,27,28]. Successive generations of the PCR systems have enabled higher resolution and more rapid detection of genes and even specific polymorphisms. Conventional PCR enables qualitative gene detection using gel electrophoresis for end-point analysis. Second-generation systems (i.e., real-time or quantitative PCR (qPCR)), generate results using a standard curve by monitoring real-time amplification with fluorescence dyes. Quantitative PCR has been effectively used for the detection of various pathogenic microorganisms, including viruses, bacteria, and fungi [1,2]. Furthermore, this technique has proven useful in the quantitative detection of pathogenic organisms in clinical settings [3]. In qPCR, results are obtained from the cycle threshold (CT), the number of cycles at which the fluorescent signal rises above the threshold set by controls. The latest generation of systems, digital PCR (dPCR), obtains the end-point result as the absolute quantification of nucleic acid concentration using Poisson statistical analyses [29]. Moreover, dPCR is a robust, highly sensitive technique with outstanding repeatability and no requirement for a standard curve [29].
Detecting the presence of efflux-associated resistance genes is paramount for informing the choice and dosage of antibiotics to treat patients clinically as well as providing potentially valuable epidemiological information [30]. While dPCR has been widely used in various applications, its specific application for detecting efflux pump genes in bacteria is limited. We hypothesized that if a novel and effective dPCR method was available for detecting efflux pump genes, it would aid the detection of drug resistance in clinical P. aeruginosa isolates. Therefore, this study aimed to develop and optimize a novel methodology herein named the “effluxR detection assay” using a multiplex digital PCR (mdPCR) system to detect the three main efflux pump genes (mexB, mexD, and mexY) in P. aeruginosa. Here, we have optimized the PCR conditions using a probe-based multiplex quantitative PCR system (mqPCR) for detection of resistance genes in P. aeruginosa. We found that the effluxR detection assay is highly sensitive and specific for identifying the presence of mexB, mexD, and mexY in P. aeruginosa from clinical isolates.

2. Materials and Methods

2.1. Bacterial Strains and Growth Conditions

The bacterial reference strains, namely Pseudomonas aeruginosa ATCC27853, P. aeruginosa ATCC BAA-2108, Staphylococcus aureus ATCC29213, S. aureus ATCC25923, Escherichia coli ATCC25922, E. coli ATCC2452, Klebsiella pneumoniae ATCC1705, and Enterobacter cloacae ATCC2341 were purchased from American Type Culture Collection (ATCC). Clinical isolates (PA.CI) of P. aeruginosa strains were received from hospitalized patients at Kamphaeng Phet Hospital, Kamphaeng Phet, Thailand in 2022. Depending on the particular experiments, tryptone soya agar (TSA; Oxoid, UK) and/or tryptone soya broth (TSB; Oxoid, UK) were used to grow each bacterium tested in this study. All the bacterial cultures were incubated at 35 ± 2 °C for 18–24 h. The turbidity of the inoculum in each experiment was equivalent to a 0.5 McFarland standard (1–2 × 108 CFU/mL) by adjustment with a densitometer (Biosan, Riga, Latvia).

2.2. Genomic DNA Extraction

All bacterial cells grown in TSB were harvested at 24 h by centrifugation. A Genomic DNA Isolation Kit (Bio-Helix, Taipei, Taiwan) was used to purify bacterial genomic DNA (gDNA) according to the manufacturer’s protocol. Briefly, the pelleted cells were lysed using the lysis buffer. The samples were then vortexed and incubated at 60 °C for 10 min. RNA was removed by adding 10 mg/mL RNase A at room temperature for 5 min. To remove protein, the protein buffer was added to the sample tubes. The samples were then centrifuged at 12,000 rpm for 1 min. Each supernatant was then collected and transferred to a 2 mL collection tube. After centrifugation, the washing buffer was added in the tube to wash the sample twice. The gDNA sample was eluted from the column with 50 µL DNase-free water and the tube was then centrifuged at 14,000 rpm for 2 min. The gDNA concentration and purity were verified using a Calibri Microvolume Spectrophotometer (Titertek-Berthold, Pforzheim, Germany).

2.3. Detection of the Mex Efflux Pump Genes Using Multiplex Quantitative PCR (mqPCR)

The isolated gDNA was used as a template to detect the mex genes using probe-based mqPCR. The 16S rRNA gene was used as a reference. The mex genes were then amplified using specific primers and probes (Table 1). The cycle threshold (CT) value was reported by measuring the change in fluorescence with each cycle. In each run, all tests were performed in triplicate with a non-template control (NTC). This approach was used to determine the optimal conditions for the effluxR detection assay.

2.3.1. Investigation of Optimal mqPCR Annealing/Extension Temperature

Five temperatures ranging from 58 to 62 °C were tested. The mqPCR reactions were prepared following the manufacturer’s guidance for the QIAcuity Probe PCR Kit (QIAGEN, Hilden, Germany). Each reaction contained 5 ng of the gDNA template, 0.8 µM of each forward and reverse primer, 0.4 µM of each probe (Table 1), 5 µL of PCR Master Mix and RNase-free water up to a total volume of 20 µL. After mixture preparation, the LineGene 9600 Plus Real-Time PCR Detection System (Bioer Technology, Hangzhou, China) was used to analyze the mex efflux pump genes in P. aeruginosa strains. The following thermal cycler conditions were used: initial denaturation at 95 °C for 2 min; 40 cycles of denaturation at 95 °C for 20 s; and combined annealing/extension at tested temperatures for 30 s.

2.3.2. Investigation of Optimal gDNA Concentration of P. aeruginosa Strains

Different gDNA concentrations were investigated for amplification of representative mex efflux pump genes in P. aeruginosa strains. To prepare the reaction, gDNA concentrations of 5.0, 2.5, 1.0, and 0.5 ng/µL were added into a PCR tube containing the same PCR reagents as above. The thermal cycler conditions were as follows: first denaturation at 95 °C for 2 min; 40 cycles of denaturation at 95 °C for 20 s; and combined annealing/extension at the optimal temperature for 30 s.

2.4. DNA Agarose Gel Electrophoresis

The expected sizes of amplicons (Table 1) were checked on 2% agarose electrophoresis gels. Briefly, 2% agarose (GeneDireX, Inc., Taoyuan, Taiwan) was prepared in Tris-borate-EDTA (TBE) buffer containing 0.5 mg/mL of UltraPure™ Ethidium Bromide (EtBr) (Cat. No. 15585011, Thermo Fisher Scientific, Waltham, MA, USA). A mixture of 10 µL PCR samples with 2 µL of a 6× loading buffer (Cat. No. LD001–1000, GeneDireX, Inc., Taoyuan, Taiwan) was loaded into the well. A DNA marker was also loaded as reference sizes (Cat. No. DM011-R500, Kplus DNA Ladder RTU, GeneDireX, Inc., Taoyuan, Taiwan). The gels were run on a Bio-Rad electrophoresis system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at constant 120 V for 30–40 min. The bands on the gels were visualized under a UV light mode of a gel documentation system (Aplegen, Ramsey, NJ, USA).

2.5. Development of the EffluxR Detection Assay to Detect the mex Efflux Pump Genes Using Multiplex Digital PCR (mdPCR)

In this study, we developed the effluxR detection assay to simultaneously detect the presence of mex efflux pump genes from the bacterial samples using the multiplex QIAcuity Digital PCR system (QIAGEN, Hilden, Germany). A QIAcuity Probe PCR Kit (QIAGEN, Hilden, Germany) was used for mdPCR reactions, following the manufacturer’s instructions. Briefly, all mdPCR reactions were performed at a final volume of 40 µL. Each reaction contained different quantities of gDNA (as indicated), 0.8 µM of each forward and reverse primer, 0.4 µM of each probe (Table 1), and 10 µL of PCR Master Mix and RNase-free water. The mdPCR reactions were then pipetted to a 24-well QIAcuity Nanoplate (QIAGEN, Hilden, Germany). The nanoplate was sealed with a rubber sheet and loaded in the QIAcuity Digital PCR instrument (QIAGEN, Hilden, Germany) (Figure 1). The thermal cycler conditions of the mdPCR system were as follows: 40 cycles of denaturation at 95 °C for 15 s and combined annealing/extension at 59 °C for 30 s. Fluorescence measurements were then made for each reaction. A non-template control (NTC) was used as a negative control. All analyzable partitions, including the valid, positive, and negative partitions, were used to calculate the total number of copies of the target molecule (λ) in all valid partitions (copies per partition) according to Equation (1). The absolute quantification (λvolume as the unit of copies/µL) was then calculated as shown in Equation (2), where the estimated partition volume (V) is 0.91 nL for the 26k-nanoplate system.
λ = ln   Number   of   valid   partitions Number   of   positive   partitions Number   of   valid   partitions
λ volume = λ V   [ µ L ]

2.5.1. Optimization of gDNA Concentration in P. aeruginosa

To determine the gDNA concentration using effluxR detection assay with the mdPCR system, a series of known concentrations of gDNA concentrations (5.00, 2.50, 1.00, 0.50, and 0.05 ng/µL) were analyzed under the optimal conditions obtained from mqPCR. The presented results were interpreted as a positive partition percentage.

2.5.2. Limit of Detection (LOD) of the effluxR Detection Assay Using the mdPCR System

To investigate the LOD of the effluxR detection assay using the mdPCR system, the gDNA concentrations of the ATCC27853 strain were diluted with RNase-free water to achieve various concentrations, including 2.50, 1.25, 0.50, 0.05, 0.005, 0.003, 0.001, and 0.000 ng/µL. The mex genes were detected as mentioned above and then interpreted as the absolute quantification in the unit of copies/µL. The 95% confidence interval (CI) in copies/µL is also reported following the manufacture’s calculation (QIAGEN, Hilden, Germany).

2.5.3. Sensitivity and Specificity Determination of the effluxR Detection Assay Using the mdPCR System

To determine the sensitivity and specificity of the effluxR detection assay with the mdPCR system, a blind test was carried out to detect 69 positive-mex efflux pump gene samples and 15 negative samples. In brief, blinded gDNA samples were mixed with a PCR probe mixture following the manufacturer’s instructions. The mexB, mexD, and mexY genes were interpreted as the percentage of positive partitions.

2.6. Statistical Analysis

The mean differences of the CT values from mqPCR were analyzed using Kruskal–Wallis one-way analysis of variance (ANOVA) in GraphPad Software (GraphPad Prism version 8.2.0, San Diego, CA, USA). Both mean CT values and standard deviations are reported. For the mdPCR system, the results were reported as the absolute quantification of the target genes, based on the number of positive and negative partitions. The correlation between absolute quantification and gDNA concentrations was analyzed using a Pearson’s correlation (two-tailed) using GraphPad Software. ROC analysis using IBM SPSS software version 23 (IBM Corp., Armonk, NY, USA) and the Youden’s index (J) were used for the validation of the cut-off values.

3. Results

3.1. Optimising Annealing/Extension Temperatures for Amplifying the RND Genes Using mqPCR

To amplify representative mex efflux pump genes of P. aeruginosa strains, the optimal mqPCR annealing/extension temperature of the genes needed to be determined for P. aeruginosa. A range of annealing/extension temperatures were tested using mqPCR including 58 °C, 59 °C, 60 °C, 61 °C, and 62 °C. Resulting cycle thresholds (CT) of mexB, mexD, and mexY, as well as the reference gene (16s rRNA) from both strains, are shown in Table 2. CT values ranged from 13.17–23.17 cycles. The results showed that the mexB gene was detected in both strains at the different annealing/extension temperatures, with the CT values ranging from 16.47–23.17 cycles. For the mexD gene, the CT value ranged from 15.57 to 17.66 cycles at the temperatures tested. The CT values of the mexY and 16s rRNA genes were detected at 15.38–17.42 and 13.17–18.92 cycles, respectively, at the temperatures tested. Overall, the result showed that all annealing/extension temperatures tested in this study were not statistically different (all p-values of > 0.9999), indicating that mexB, mexD, and mexY genes successfully amplified in P. aeruginosa ATCC27853 and P. aeruginosa ATCC BAA-2108 between 58 and 62 °C.

3.2. Optimal gDNA Concentration of P. aeruginosa ATCC for Amplifying the Mex Genes Using mqPCR

To optimize the gDNA concentrations for the amplification of the mex efflux pump genes using the mqPCR system, we used the optimal annealing/extension temperature of 59 °C. All gDNA concentrations tested (5.0, 2.5, 1.0, and 0.5 ng/µL) showed the CT values ranging from 15.49–27.31 cycles of all mexB, mexD, mexY, and 16s rRNA genes (Table 3). For mexB of both P. aeruginosa strains, the CT values of gDNA concentrations tested ranged from 17.97–27.31 cycles. In both P. aeruginosa genome samples, the CT values of mexD were shown in the range from 19.80–22.93 cycles at the gDNA concentrations tested. At the same time, the mexY gene of both P. aeruginosa strains tested showed CT values ranging from 18.98–22.17 cycles. For the reference gene, 16s rRNA, at gDNA concentrations tested, the CT value was shown in the range from 15.49–21.04 cycles (Table 3). This result indicated that the gDNA samples of P. aeruginosa ATCC27853 and P. aeruginosa ATCC BAA-2108 in all concentrations tested had strong positive reactions, indicating that they are suitable for detection of the mex efflux pump genes in these samples.

3.3. MexB, mexD, mexY, and 16s rRNA Bands were Detected in All P. aeruginosa Strains Using Agarose Gel Electrophoresis

We sought to verify that the amplicons generated using the optimized mqPCR conditions were of the anticipated size by agarose gel electrophoresis (Figure 2B). Genomic DNA (5 ng) were amplified at 59 °C with the mex and reference primer sets. The results showed that the amplicons of the reference gene, 16s rRNA, in all P. aeruginosa gDNA samples were of the expected size of 225 bp (Figure 2A,B; Table 1). The amplicons for the mexB, mexD, and mexY genes were shown near 199 bp, 131 bp, and 168 bp, respectively (Figure 2A,B), as expected (Table 1). The results confirmed that the optimal conditions for mqPCR (including the annealing/extension temperatures, concentration of the gDNA and specific primer sets) were suitable for amplifying the drug resistance genes in the P. aeruginosa strains tested.

3.4. The Mex Efflux Pump Genes Can Be Detected at a Range of gDNA Concentrations in P. aeruginosa Using the effluxR Detection Assay with the mdPCR System

We examined the presence of representative mex efflux pump genes, including mexB, mexD, and mexY of P. aeruginosa ATCC27853, at various gDNA concentrations using the effluxR detection assay with the mdPCR system. The positive and negative partitions of each mex gene in P. aeruginosa were presented as the relative fluorescent intensity units on a 1D scatter plot (Figure 3). At the same time, microscopic image validation was used to identify the specific mex target genes using specific fluorescent dyes in the filled partitions (Figure 4). The aggregated results of all three replicates demonstrated a concentration-dependent signal with strong fluorescence intensities of all genes tested, which would enable absolute quantification of gene copies. For P. aeruginosa gDNA concentrations of 5.00 ng/µL, the positive partitions of mexB, mexD, and mexY genes were 100%. At a gDNA concentration of 2.50 ng/µL, the positive partitions were 100%, 100%, and 96.33% for mexB, mexD, and mexY, respectively, while the positive partitions of mexB, mexD, and mexY with 1.00 ng/µL of gDNA were 99.33%, 97.00% and 82.00%, respectively. For P. aeruginosa gDNA concentrations of 0.50 ng/µL, the positive partitions were 88.67%, 84.67%, and 72.33% for mexB, mexD, and mexY, respectively. Finally, with 0.05 ng/µL gDNA concentration, the positive partitions were 58.00%, 36.67%, and 31.67% for mexB, mexD, and mexY, respectively.

3.5. Detection Limit of the effluxR Detection Assay with the mdPCR System Is 0.001 ng/µL Equivalent to 7.04 copies/µL of the Mex Efflux Pump Genes in P. aeruginosa ATCC27853

The limit of detection (LOD) for the effluxR detection assay using the mdPCR platform was determined by detecting the presence of representative mex efflux pump genes at a range of genomic concentrations of the P. aeruginosa strain, ATCC27853. Concentrations assayed include 2.50 ng/µL, 1.25 ng/µL, 0.50 ng/µL, 0.05 ng/µL, 0.005 ng/µL, 0.003 ng/µL, and 0.001 ng/µL. In all three replicates of each PCR reaction, we successfully detected and determined the absolute number of the mex genes (copies/µL) in the samples with gDNA concentrations ranging from 0.001–2.50 ng/µL (Table 4). Of note, small amounts of background signals detected in the non-template controls led to absolute quantification values lower than 0.5 copies/µL. This result confirmed that the absolute quantification of mexB, mexD, and mexY would decrease with lower gDNA concentrations. The ranges of the absolute quantification of mexB, mexD, and mexY in the samples were 34.81–10,388.27, 15.52–9121.83, and 7.04–5626.67 copies/µL, respectively. Hence, the absolute quantification was attainable from gDNA concentrations of 0.001 ng/µL or higher. As a result, we conclude that the detection limit for the mex efflux pump target genes using the effluxR detection assay with mdPCR was 0.001 ng/µL. Moreover, there was a good correlation between the gDNA concentrations and the absolute quantification of mexB, mexD, and mexY at R2 values of 0.78 (p = 0.0035), 0.87 (p = 0.0007), and 0.95 (p < 0.0001), respectively. We also reported a cut-off value of 3.72 copies/µL for detecting the presence of mex efflux genes with the max Youden’s index (J) of 1 (Table 5).

3.6. Sensitivity and Specificity of the effluxR Detection Assay with mdPCR System Were 100% for Detecting the Mex Efflux Pump Genes in the P. aeruginosa Strains

After determining the limit of detection, a sample-blinded investigation was conducted to evaluate the sensitivity and specificity of the effluxR detection assay with the mdPCR system for detecting the mex efflux pump genes in P. aeruginosa strains. We set up the blinded samples which included 69 known positive samples and 15 known negative samples for the mex efflux pump genes. The blinded samples were randomly numbered from Sample 1 to 84 (Table 6). The assay identified the positive partitions of mexB, mexD, and mexY in all positive samples, which is represented as the relative fluorescence intensity in Figure 5. The cut-off value for interpretation was applied among all blinded samples and the non-template control. Using this assay with the mdPCR system, all the mex genes, including mexB, mexD, and mexY, were detected in all positive samples (100%), while the mex genes were not detected in any negative samples (100%) (Table 6). The blinded investigation showed 100% sensitivity and specificity for the identification of the mex efflux pump genes in the P. aeruginosa strains. In addition, we did not detect mexB, mexD, and mexY in negative blinded samples from other bacterial strains, further confirming species specificity, namely S. aureus ATCC29213, S. aureus ATCC25923, E. coli ATCC25922, E. coli ATCC2452, K. pneumoniae ATCC1705, and E. cloacae ATCC2341 (Table 6).

4. Discussion

The use of efflux pumps is one of the major mechanisms of antibiotic resistance in P. aeruginosa, as they facilitate the expulsion of antibiotics or compounds across the outer membrane [18]. The resistance-nodulation-division (RND) efflux pump mechanism constitutes a substantial driver of drug and multidrug resistance in P. aeruginosa [19]. Notably, antibiotic resistance is primarily influenced by at least three pivotal RND pumps, namely the MexAB-OprM, MexCD-OprJ, and MexXY(-OprA) systems [18,20]. In this work, we sought to detect the presence of mexB, mexD, and mexY genes, which encode efflux pump factors in P. aeruginosa strains using a multiplex digital PCR assay. The mdPCR assay can handle multiple targets, making it a valuable tools for large-scale studies and clinical applications [32]. For example, MexA and MexB are parts of the MexAB-OprM efflux pump system, which is responsible for resistance to a broad range of antibiotics, including beta-lactams and fluoroquinolones [33]. MexC and MexD are parts of the MexCD-OprJ efflux pump system, which is related with resistance to fluoroquinolones and other antimicrobials [34]. MexX and MexY are parts of the MexXY-OprM/OprA efflux pump system, which confers resistance to aminoglycosides and other antimicrobial agents [24]. However, there are at least 10 RND-type efflux pump systems of P. aeruginosa located in other operons which have yet to be characterized in detail [35]. Here, the three RND systems of greatest significance to antibiotic resistance are studied as they confer resistance to antibiotics including beta-lactams and fluoroquinolones [18,20,21]. Using our effluxR detection assay with mdPCR, the presence of these mex genes was detected with high specificity in P. aeruginosa strains, but not in any of the other bacterial strains investigated. P. aeruginosa’s core genome encodes many RND-type efflux pumps, e.g., MexXY, MexAB-OprM, MexCD-OprJ [36], while other microorganism genomes encode other unique types of the RND superfamily efflux pumps, e.g., E. coli (AcrAB, AcrAD, AcrEF) [37], K. pneumoniae (AcrAB, OqxAB, EefAB, KexD) [38], E. cloacae (AcrAB-TolC) [39], S. aureus (FarE) [40]. According to the high R2 values, the absolute quantification of mexB, mexD, and mexY correlates with the gDNA concentrations. As a result, we believe that this assay can be applied to rapidly and accurately detect the presence of mex genes in clinical isolates of P. aeruginosa. In addition, the effluxR detection assay with mdPCR permits detection of genes with gDNA concentrations as low as 0.001 ng/mL (equivalent to 7.04–34.81 copies/µL). Therefore, we propose an appropriate cut-off value of at least 3.72 copies/µL. Absolute quantitative values enable digital PCR results to be used without calibrators or normalisation that would otherwise be required with qPCR [26]. However, the PCR-based technique including qPCR and dPCR has some limitations, such as if the targeted genes contain mutations. If the site of the mutation is located in the primer binding sites, the ability to generate an amplicon would potentially be impaired. However, other genotypic methods could be performed to detect the PCR products containing mutations such as single-stranded conformational polymorphism (SSCP) analysis or sequencing [41].
Genotypic methods such as PCR, RT-PCR, and digital PCR offer several significant advantages over phenotypic assays for assessing efflux pump genes in bacteria [32,42]. Digital PCR is more sensitive and can be further applied to detect the presence of resistance genes at low levels of efflux pump expression [31], thereby providing insights into the role of efflux pumps in the acquisition of antibiotic resistance. Additionally, mdPCR allows the detection of multiple efflux pump genes in a single reaction. Furthermore, genotypic methods are not dependent on growth-based assays and can be performed directly on bacterial DNA or RNA samples, reducing the time and resources required for analysis [32]. Finally, these genotypic methods are not affected by efflux pump inhibitors, providing more robust and reproducible results compared with phenotypic assays. There are several phenotypic assays for efflux pump activity in bacteria that are employed to determine the presence and functionality of efflux pumps, e.g., ethidium bromide/fluorescent dye accumulation assay, efflux pump inhibitor (EPI) assay, etc. [43,44,45]. Nevertheless, these assays have some limitations and disadvantages. Notably, the ethidium bromide (EtBr) accumulation assay lacks specificity due to EtBr’s status as a general substrate that can be extruded by multiple efflux pumps, thus complicating the differentiation between distinct efflux pump types [40,46]. Of further note, EtBr is a mutagenic and hazardous chemical, posing safety concerns, necessitating stringent safety measures during handling and careful disposal to mitigate exposure risks [47]. Moreover, alterations in fluorescence signals in fluorescent dye accumulation assays may be influenced by factors unrelated to efflux pump activity, such as changes in membrane permeability or metabolic state, potentially leading to erroneous interpretations of efflux pump functionality [48]. Furthermore, the efficacy of EPIs may vary across different efflux pumps, resulting in inconsistent inhibition results and impeding direct comparisons among diverse bacterial strains or species [49].
Use of the effluxR detection assay with mdPCR serves as a rapid and quantitative diagnostic test as well as a potential tool for early detection of drug resistance, leading to better clinical outcomes and improved antibiotic stewardship in the management of bacterial infections. We recommend the application of the effluxR detection assay with multiplex digital PCR for the identification of RND-type resistance genes for rapid, sensitive, and specific detection of P. aeruginosa antibiotic resistance. However, this assay should be further investigated in the clinical samples, e.g., blood, sputum, pus, etc. Detecting one of these resistance genes could be used as a genomic-marker identification for P. aeruginosa strains, thereby enabling rapid diagnosis of P. aeruginosa infections. Further development of this methodology could also permit further uses such as bacterial or fungal pathogen identification, enzyme-mediated resistance gene detection and expression, porin gene expression analysis, and/or the identification and expression of individual RND-efflux pumps.

5. Conclusions

Here we show that an effluxR detection assay with mdPCR is a high-performance tool for simultaneously detecting the presence of three different mex efflux pump genes (mexB, mexD, and mexY) as indicators of drug resistance in clinical P. aeruginosa strains. The optimal conditions for detecting mexB, mexD, and mexY using mdPCR were 40 cycles of denaturation at 95 °C for 15 s and combined annealing/extension at 59 °C for 30 s, while the gDNA concentrations ranged from 0.5–5.0 ng/µL. The gDNA detection limit for this assay for mexB, mexD, and mexY genes was 0.001 ng/µL. We also highlight that the effluxR detection assay with mdPCR system had 100% sensitivity and specificity for the gene identification with the cut-off value of greater than or equal to 3.72 copies/µL in a blinded sample test. In conclusion, the effluxR detection assay with the mdPCR system is suitable to amplify and detect mex genes in P. aeruginosa strains. In the future, using the effluxR detection assay with mdPCR systems to detect mex genes has the potential to significantly aid clinical decision making for P. aeruginosa and reduce inappropriate antibiotic use by rationalizing the choice and dosage of antibiotics for P. aeruginosa infectious treatment.

Author Contributions

Conceptualization, N.R., T.J. (Touchkanin Jongjitvimol) and J.J.; methodology, N.R., T.J. (Touchkanin Jongjitvimol) and J.J.; validation, N.R., S.W., T.J. (Touchkanin Jongjitvimol) and J.J.; formal analysis, N.R., T.J. (Touchkanin Jongjitvimol) and J.J.; investigation, N.R., T.J. (Theerasak Jaifoo), T.J. (Touchkanin Jongjitvimol) and J.J.; resources, T.J. (Touchkanin Jongjitvimol) and J.J.; data curation, N.R. and J.J.; writing—original draft preparation, N.R., R.A.B., T.J. (Touchkanin Jongjitvimol) and J.J.; writing—review and editing, N.R., S.W., R.A.B., T.J. (Theerasak Jaifoo), T.J. (Touchkanin Jongjitvimol) and J.J.; visualization, T.J. (Touchkanin Jongjitvimol) and J.J.; supervision, T.J. (Touchkanin Jongjitvimol) and J.J.; project administration, T.J. (Touchkanin Jongjitvimol) and J.J.; funding acquisition, N.R., R.A.B., T.J. (Touchkanin Jongjitvimol) and J.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by National Science, Research and Innovation Fund (NSRF), grant number R2564B019 (J.J.) and the Global and Frontier Research University Grant, grant number R2566C052 (J.J.). This research was also partly funded by Pibulsongkram Rajabhat University (Research Fund from the Research and Development Institute: RDI-2-65-44, and Fundamental Fund: fiscal year 2024) (T.J.). N.R. thankfully acknowledges funding from the Royal Thai Government, grant number 3/2563. R.A.B. gratefully acknowledges funding from the Royal Society, grant number RGS\R2\192126.

Institutional Review Board Statement

This study is not applicable due to not involving humans or animals. According to the Biosafety and Biosecurity aspects, this work was approved by the Naresuan University Institutional Biosafety Committee (NUIBC no. 64-16) and (NUIBC MI 65-05-10).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data supporting the current study are available from the corresponding author upon request.

Acknowledgments

Thanks to all facilities of the Faculty of Allied Health Sciences, Naresuan University and the Faculty of Science and Technology, Pibulsongkram Rajabhat University. We also thank all of the research funders.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhanel, G.G.; DeCorby, M.; Adam, H.; Mulvey, M.R.; McCracken, M.; Lagacé-Wiens, P.; Nichol, K.A.; Wierzbowski, A.; Baudry, P.J.; Tailor, F.; et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008). Antimicrob. Agents Chemother. 2010, 54, 4684–4693. [Google Scholar] [CrossRef]
  2. Mahar, P.; Padiglione, A.A.; Cleland, H.; Paul, E.; Hinrichs, M.; Wasiak, J. Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes. Burns 2010, 36, 1228–1233. [Google Scholar] [CrossRef] [PubMed]
  3. Lambert, M.L.; Suetens, C.; Savey, A.; Palomar, M.; Hiesmayr, M.; Morales, I.; Agodi, A.; Frank, U.; Mertens, K.; Schumacher, M.; et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. Lancet Infect. Dis. 2011, 11, 30–38. [Google Scholar] [CrossRef]
  4. Alp, E.; Güven, M.; Yıldız, O.; Aygen, B.; Voss, A.; Doganay, M. Incidence, risk factors and mortality of nosocomial pneumonia in Intensive Care Units: A prospective study. Ann. Clin. Microbiol. Antimicrob. 2004, 3, 17. [Google Scholar] [CrossRef]
  5. Aliaga, L.; Mediavilla, J.D.; Cobo, F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia. J. Med. Microbiol. 2002, 51, 615–701. [Google Scholar] [CrossRef] [PubMed]
  6. Klockgether, J.; Cramer, N.; Wiehlmann, L.; Davenport, C.; Tümmler, B. Pseudomonas aeruginosa genomic structure and diversity. Front. Microbiol. 2011, 2, 150. [Google Scholar] [CrossRef]
  7. Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warrener, P.; Hickey, M.J.; Brinkman, F.S.L.; Hufnagle, W.O.; Kowalik, D.J.; Lagrou, M.; et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406, 959–964. [Google Scholar] [CrossRef] [PubMed]
  8. Poole, K. Outer membranes and efflux: The path to multidrug resistance in Gram-negative bacteria. Curr. Pharm. Biotechnol. 2002, 3, 77–98. [Google Scholar] [CrossRef]
  9. Hirsch, E.B.; Tam, V.H. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev. Pharmacoecon. Outcomes Res. 2010, 10, 441–451. [Google Scholar] [CrossRef]
  10. Kallen, A.J.; Hidron, A.I.; Patel, J.; Srinivasan, A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect. Control. Hosp. Epidemiol. 2010, 31, 528–531. [Google Scholar] [CrossRef] [PubMed]
  11. Kerr, K.G.; Snelling, A.M. Pseudomonas aeruginosa: A formidable and ever-present adversary. J. Hosp. Infect. 2009, 73, 338–344. [Google Scholar] [CrossRef]
  12. Peña, C.; Cabot, G.; Gómez-Zorrilla, S.; Zamorano, L.; Ocampo-Sosa, A.; Murillas, J.; Almirante, B.; Pomar, V.; Aguilar, M.; Granados, A.; et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin. Infect. Dis. 2015, 60, 539–548. [Google Scholar] [CrossRef] [PubMed]
  13. Sader, H.S.; Castanheira, M.; Duncan, L.R.; Flamm, R.K. Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States Medical Centers stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, 2015–2016. Diagn. Microbiol. Infect. Dis. 2018, 92, 69–74. [Google Scholar] [CrossRef] [PubMed]
  14. Walkty, A.; Lagace-Wiens, P.; Adam, H.; Baxter, M.; Karlowsky, J.; Mulvey, M.R.; McCracken, M.; Zhanel, G.G. Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008–2015. Diagn. Microbiol. Infect. Dis. 2017, 87, 60–63. [Google Scholar] [CrossRef]
  15. Frieri, M.; Kumar, K.; Boutin, A. Antibiotic resistance. J. Infect. Public Health 2017, 10, 369–378. [Google Scholar] [CrossRef]
  16. Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.-J.; Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019, 37, 177–192. [Google Scholar] [CrossRef]
  17. Bouzid, D.; Zanella, M.C.; Kerneis, S.; Visseaux, B.; May, L.; Schrenzel, J.; Cattoir, V. Rapid diagnostic tests for infectious diseases in the emergency department. Clin. Microbiol. Infect. 2021, 27, 182–191. [Google Scholar] [CrossRef]
  18. Dreier, J.; Ruggerone, P. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front. Microbiol. 2015, 6, 660. [Google Scholar] [CrossRef]
  19. Colclough, A.L.; Alav, I.; Whittle, E.E.; Pugh, H.L.; Darby, E.M.; Legood, S.W.; McNeil, H.E.; Blair, J.M. RND efflux pumps in Gram-negative bacteria; regulation, structure and role in antibiotic resistance. Future Microbiol. 2020, 15, 143–157. [Google Scholar] [CrossRef]
  20. Fernández, L.; Hancock, R.E.W. Adaptive and mutational resistance: Role of porins and efflux pumps in drug resistance. Clin. Microbiol. Rev. 2012, 25, 661–681. [Google Scholar] [CrossRef] [PubMed]
  21. Aghazadeh, M.; Hojabri, Z.; Mahdian, R.; Nahaei, M.R.; Rahmati, M.; Hojabri, T.; Pirzadeh, T.; Pajand, O. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients. Infect. Genet. Evol. 2014, 24, 187–192. [Google Scholar] [CrossRef] [PubMed]
  22. Lister, P.D.; Wolter, D.J.; Hanson, N.D. Antibacterial-resistant Pseudomonas aeruginosa: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 2009, 22, 582–610. [Google Scholar] [CrossRef]
  23. Venter, H.; Mowla, R.; Ohene-Agyei, T.; Ma, S. RND-type drug efflux pumps from Gram-negative bacteria: Molecular mechanism and inhibition. Front. Microbiol. 2015, 6, 377. [Google Scholar] [CrossRef] [PubMed]
  24. Morita, Y.; Tomida, J.; Kawamura, Y. MexXY multidrug efflux system of Pseudomonas aeruginosa. Front. Microbiol. 2012, 3, 408. [Google Scholar] [CrossRef] [PubMed]
  25. Poole, K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 2005, 56, 20–51. [Google Scholar] [CrossRef] [PubMed]
  26. Hindson, B.J.; Ness, K.D.; Masquelier, D.A.; Belgrader, P.; Heredia, N.J.; Makarewicz, A.J.; Bright, I.J.; Lucero, M.Y.; Hiddessen, A.L.; Legler, T.C.; et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 2011, 83, 8604–8610. [Google Scholar] [CrossRef]
  27. Galhano, B.S.P.; Ferrari, R.G.; Panzenhagen, P.; de Jesus, A.C.S.; Conte-Junior, C.A. Antimicrobial resistance gene detection methods for bacteria in animal-based foods: A brief review of highlights and advantages. Microorganisms 2021, 9, 923. [Google Scholar] [CrossRef]
  28. Seedy, F.R.E.; Samy, A.A.; Salam, H.S.H.; Khairy, E.A.; Koraney, A.A. Polymerase chain reaction detection of genes responsible for multiple antibiotic resistance Staphylococcus aureus isolated from food of animal origin in Egypt. Vet. World 2017, 10, 1205–1211. [Google Scholar] [CrossRef]
  29. Ahmed, W.; Smith, W.J.M.; Metcalfe, S.; Jackson, G.; Choi, P.M.; Morrison, M.; Field, D.; Gyawali, P.; Bivins, A.; Bibby, K.; et al. Comparison of RT-qPCR and RT-dPCR platforms for the trace detection of SARS-CoV-2 RNA in wastewater. ACS ES&T Water 2022, 2, 1871–1880. [Google Scholar] [CrossRef]
  30. Mesaros, N.; Glupczynski, Y.; Avrain, L.; Caceres, N.E.; Tulkens, P.M.; Van Bambeke, F. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2007, 59, 378–386. [Google Scholar] [CrossRef]
  31. Rattanachak, N.; Weawsiangsang, S.; Jongjitvimol, T.; Baldock, R.A.; Jongjitwimol, J. Hydroquinine possesses antibacterial activity, and at half the MIC, induces the overexpression of RND-type efflux pumps using Multiplex Digital PCR in Pseudomonas aeruginosa. Trop. Med. Int. Health 2022, 7, 156. [Google Scholar] [CrossRef]
  32. Kaprou, G.D.; Bergšpica, I.; Alexa, E.A.; Alvarez-Ordóñez, A.; Prieto, M. Rapid methods for antimicrobial resistance diagnostics. Antibiotics 2021, 10, 209. [Google Scholar] [CrossRef] [PubMed]
  33. Nakae, T.; Nakajima, A.; Ono, T.; Saito, K.; Yoneyama, H. Resistance to beta-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and beta-lactamase. Antimicrob. Agents Chemother. 1999, 43, 1301–1303. [Google Scholar] [CrossRef] [PubMed]
  34. Bialvaei, A.Z.; Rahbar, M.; Hamidi-Farahani, R.; Asgari, A.; Esmailkhani, A.; Dashti, Y.M.; Soleiman-Meigooni, S. Expression of RND efflux pumps mediated antibiotic resistance in Pseudomonas aeruginosa clinical strains. Microb. Pathog. 2021, 153, 104789. [Google Scholar] [CrossRef]
  35. Schweizer, H.P. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: Unanswered questions. Genet. Mol. Res. 2003, 2, 48–62. [Google Scholar] [PubMed]
  36. Valot, B.; Guyeux, C.; Rolland, J.Y.; Mazouzi, K.; Bertrand, X.; Hocquet, D. What It takes to be a Pseudomonas aeruginosa? The core genome of the opportunistic pathogen updated. PLoS ONE 2015, 10, e0126468. [Google Scholar] [CrossRef]
  37. Anes, J.; McCusker, M.P.; Fanning, S.; Martins, M. The ins and outs of RND efflux pumps in Escherichia coli. Front. Microbiol. 2015, 6, 587. [Google Scholar] [CrossRef]
  38. Ni, R.T.; Onishi, M.; Mizusawa, M.; Kitagawa, R.; Kishino, T.; Matsubara, F.; Tsuchiya, T.; Kuroda, T.; Ogawa, W. The role of RND-type efflux pumps in multidrug-resistant mutants of Klebsiella pneumoniae. Sci. Rep. 2020, 10, 10876. [Google Scholar] [CrossRef]
  39. Guérin, F.; Lallement, C.; Isnard, C.; Dhalluin, A.; Cattoir, V.; Giard, J.C. Landscape of Resistance-Nodulation-Cell Division (RND)-type efflux pumps in Enterobacter cloacae complex. Antimicrob. Agents Chemother. 2016, 60, 2373–2382. [Google Scholar] [CrossRef]
  40. Dashtbani-Roozbehani, A.; Brown, M.H. Efflux pump mediated antimicrobial resistance by Staphylococci in health-related environments: Challenges and the quest for inhibition. Antibiotics 2021, 10, 1502. [Google Scholar] [CrossRef]
  41. Frayling, I.M.; Monk, E.; Butler, R. PCR-Based Methods for Mutation Detection. In Molecular Diagnostics: For the Clinical Laboratorian; Coleman, W.B., Tsongalis, G.J., Eds.; Humana Press: Totowa, NJ, USA, 2005; pp. 65–74. [Google Scholar]
  42. Huletsky, A.; Bergeron, M.G. Bacterial Genotypic Drug Resistance Assays. In Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects; Mayers, D.L., Sobel, J.D., Ouellette, M., Kaye, K.S., Marchaim, D., Eds.; Springer International Publishing: Cham, Switzerland, 2017; Volume 2, pp. 1465–1499. [Google Scholar]
  43. Martins, M.; Santos, B.; Martins, A.; Viveiros, M.; Couto, I.; Cruz, A.; Pagès, J.M.; Molnar, J.; Fanning, S.; Amaral, L. An instrument-free method for the demonstration of efflux pump activity of bacteria. In Vivo 2006, 20, 657–664. [Google Scholar] [PubMed]
  44. Martins, M.; Couto, I.; Viveiros, M.; Amaral, L. Identification of efflux-mediated multi-drug resistance in bacterial clinical isolates by two simple methods. Methods Mol. Biol. 2010, 642, 143–157. [Google Scholar] [CrossRef] [PubMed]
  45. Cattoir, V. Efflux-mediated antibiotics resistance in bacteria. Pathol. Biol. 2004, 52, 607–616. [Google Scholar] [CrossRef]
  46. Paixão, L.; Rodrigues, L.; Couto, I.; Martins, M.; Fernandes, P.; de Carvalho, C.C.C.R.; Monteiro, G.A.; Sansonetty, F.; Amaral, L.; Viveiros, M. Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. J. Biol. Eng. 2009, 3, 18. [Google Scholar] [CrossRef]
  47. Saeidnia, S.; Abdollahi, M. Are other fluorescent tags used instead of ethidium bromide safer? DARU J. Pharm. Sci. 2013, 21, 71. [Google Scholar] [CrossRef]
  48. Whittle, E.E.; McNeil, H.E.; Trampari, E.; Webber, M.; Overton, T.W.; Blair, J.M.A. Efflux impacts intracellular accumulation only in actively growing bacterial cells. mBio 2021, 12, e0260821. [Google Scholar] [CrossRef] [PubMed]
  49. Lomovskaya, O.; Warren, M.S.; Lee, A.; Galazzo, J.; Fronko, R.; Lee, M.; Blais, J.; Cho, D.; Chamberland, S.; Renau, T.; et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob. Agents Chemother. 2001, 45, 105–116. [Google Scholar] [CrossRef]
Figure 1. The schematic amplification of target genes using digital PCR.
Figure 1. The schematic amplification of target genes using digital PCR.
Mps 06 00096 g001
Figure 2. Agarose gel electrophoresis analysis of the reference (16s rRNA) and mex efflux pump genes (mexB, mexD, and mexY) amplified with (A) singleplex PCR system from representative P. aeruginosa ATCC 27853 strains and (B) multiplex PCR system from five representative P. aeruginosa strains. The PCR products amplified were run on a 2% agarose gel. The gDNA concentration was 5 ng/µL (the gDNA amount was 5 ng). The first lane contains a DNA ladder of fragments of known sizes. “PA. 27853” is the sample from P. aeruginosa ATCC27853. “PA. 2108” is the sample from P. aeruginosa ATCC BAA-2108. “PA. CI1, PA. CI2, and PA. CI3”, are the samples from P. aeruginosa clinical isolate no. 1, no. 2, and no. 3, respectively. NTC denotes the non-template control.
Figure 2. Agarose gel electrophoresis analysis of the reference (16s rRNA) and mex efflux pump genes (mexB, mexD, and mexY) amplified with (A) singleplex PCR system from representative P. aeruginosa ATCC 27853 strains and (B) multiplex PCR system from five representative P. aeruginosa strains. The PCR products amplified were run on a 2% agarose gel. The gDNA concentration was 5 ng/µL (the gDNA amount was 5 ng). The first lane contains a DNA ladder of fragments of known sizes. “PA. 27853” is the sample from P. aeruginosa ATCC27853. “PA. 2108” is the sample from P. aeruginosa ATCC BAA-2108. “PA. CI1, PA. CI2, and PA. CI3”, are the samples from P. aeruginosa clinical isolate no. 1, no. 2, and no. 3, respectively. NTC denotes the non-template control.
Mps 06 00096 g002
Figure 3. The fluorescence intensity of mex efflux pump genes at various gDNA concentrations of P. aeruginosa ATCC27853, detected by multiplex digital PCR, for (A) mexB, (B) mexD, and (C) mexY. Abbreviation; RFU: relative fluorescence units, NTC: Non-template control. The red lines represent the fluorescence threshold. Blue dots above the threshold line are considered as positive partitions, whereas grey dots below the threshold line are considered as negative partitions.
Figure 3. The fluorescence intensity of mex efflux pump genes at various gDNA concentrations of P. aeruginosa ATCC27853, detected by multiplex digital PCR, for (A) mexB, (B) mexD, and (C) mexY. Abbreviation; RFU: relative fluorescence units, NTC: Non-template control. The red lines represent the fluorescence threshold. Blue dots above the threshold line are considered as positive partitions, whereas grey dots below the threshold line are considered as negative partitions.
Mps 06 00096 g003
Figure 4. The validated microscopic images of mexB gene as the representative for positive reactions (AE) and a negative reaction (F) in various gDNA concentrations of P. aeruginosa ATCC27853: (A) 5 ng/µL; (B) 2.5 ng/µL; (C) 1.0 ng/µL; (D) 0.5 ng/µL; (E) 0.05 ng/µL; and (F) non-template. The green dots represent the positive partitions containing the target genes.
Figure 4. The validated microscopic images of mexB gene as the representative for positive reactions (AE) and a negative reaction (F) in various gDNA concentrations of P. aeruginosa ATCC27853: (A) 5 ng/µL; (B) 2.5 ng/µL; (C) 1.0 ng/µL; (D) 0.5 ng/µL; (E) 0.05 ng/µL; and (F) non-template. The green dots represent the positive partitions containing the target genes.
Mps 06 00096 g004
Figure 5. Representative fluorescence intensity of positive-mex efflux pump gene samples and negative samples: (A) 5 ng/µL of P. aeruginosa ATCC27853; (B) 5 ng/µL of P. aeruginosa clinical isolate; (C) 5 ng/µL of K. pneumoniae ATCC1705; and (D) non-template. The red lines represent the fluorescence threshold. Blue dots above the threshold line are considered as positive partitions, whereas grey dots below the threshold line are considered as negative partitions.
Figure 5. Representative fluorescence intensity of positive-mex efflux pump gene samples and negative samples: (A) 5 ng/µL of P. aeruginosa ATCC27853; (B) 5 ng/µL of P. aeruginosa clinical isolate; (C) 5 ng/µL of K. pneumoniae ATCC1705; and (D) non-template. The red lines represent the fluorescence threshold. Blue dots above the threshold line are considered as positive partitions, whereas grey dots below the threshold line are considered as negative partitions.
Mps 06 00096 g005
Table 1. The primer and probe sequences were used in this study.
Table 1. The primer and probe sequences were used in this study.
NameOligonucleotide Sequences (5′ to 3′)PCR Product Size (bp)References
mexB199[31]
F_primerGATAGGCCCATTTTCGCGTGG
R_primerCGATCCCGTTCATCTGCTGC
Probe(FAM)CGCCTTGGTGATCATGCTCGCG(BHQ1)
mexD131[31]
F_primerTCATCAAGCGGCCGAACTTC
R_primerGGTGGCGGTGATGGTGATCTG
Probe(HEX)CTGGCCGGCCTGCTGGTCATTTC(BHQ1)
mexY168[31]
F_primerCGCAACTGACCCGCTACAAC
R_primerCGGACAGGCGTTCTTCGAAG
Probe(Texas Red)CGAAGCCATGCAGGCGATGGAGG(BHQ2)
16s rRNA225[31]
F_primerCATGGCTCAGATTGAACGCTG
R_primerGCTAATCCGACCTAGGCTCATC
Probe(Cy5)CGAGCGGATGAAGGGAGCTTGCTC(BHQ2)
Table 2. The various annealing/extension temperatures and the cycle threshold (CT) values of each gene were detected in two P. aeruginosa strains using multiplex qPCR.
Table 2. The various annealing/extension temperatures and the cycle threshold (CT) values of each gene were detected in two P. aeruginosa strains using multiplex qPCR.
StrainsGenesCycle Threshold Values in Gradient Annealing/Extension Temperature (°C)p-Value
5859606162
P. aeruginosa
ATCC27853
mexB16.50 ± 1.1016.47 ± 1.1316.53 ± 1.3716.48 ± 1.7716.99 ± 1.89>0.9999
mexD16.24 ± 0.9515.57 ± 0.9715.99 ± 1.5716.69 ± 1.0417.66 ± 1.16>0.9999
mexY16.12 ± 0.9815.38 ± 1.1015.76 ± 1.8716.38 ± 1.1817.31 ± 1.45>0.9999
16S rRNA13.17 ± 1.6013.50 ± 0.3314.03 ± 0.9614.56 ± 1.4514.67 ± 0.42>0.9999
P. aeruginosa
ATCC BAA-2108
mexB19.77 ± 0.9820.61 ± 1.3420.81 ± 0.8021.21 ± 0.6023.17 ± 1.08>0.9999
mexD16.87 ± 0.6216.78 ± 1.2116.40 ± 0.1716.20 ± 0.1716.85 ± 1.50>0.9999
mexY16.75 ± 0.3316.79 ± 1.2016.38 ± 0.3416.47 ± 0.2717.42 ± 0.24>0.9999
16S rRNA13.37 ± 0.6316.99 ± 0.5617.35 ± 1.3818.92 ± 0.6718.58 ± 1.23>0.9999
Table 3. P. aeruginosa gDNA concentrations and cycle threshold (CT) values for detection of each mex gene in two P. aeruginosa strains using multiplex qPCR.
Table 3. P. aeruginosa gDNA concentrations and cycle threshold (CT) values for detection of each mex gene in two P. aeruginosa strains using multiplex qPCR.
StrainsTarget GenesThe CT Values in the Different gDNA Concentrationsp-Value
5.0 ng/µL2.5 ng/µL1.0 ng/µL0.5 ng/µL
P. aeruginosa ATCC27853mexB17.97 ± 1.3118.93 ± 0.9222.65 ± 0.6923.07 ± 1.26>0.9999
mexD20.56 ± 0.9319.92 ± 0.9221.74 ± 0.4522.50 ± 0.52>0.9999
mexY19.39 ± 0.6118.98 ± 0.6821.71 ± 0.8022.17 ± 1.12>0.9999
16S rRNA15.49 ± 0.9017.80 ± 0.6921.04 ± 0.9320.80 ± 0.39>0.9999
P. aeruginosa ATCC
BAA-2108
mexB20.14 ± 0.2422.98 ± 0.7823.86 ± 0.2227.31 ± 1.21>0.9999
mexD21.23 ± 0.5919.80 ± 0.2220.92 ± 0.4122.93 ± 0.91>0.9999
mexY19.16 ± 0.9519.18 ± 0.9020.61 ± 0.5420.65 ± 1.54>0.9999
16S rRNA17.44 ± 1.2016.34 ± 0.3519.61 ± 1.3020.97 ± 0.61>0.9999
Table 4. Absolute quantification (copies/µL) and 95% confidence interval (95% CI) of representative mex efflux pump genes presented in various P. aeruginosa ATCC27853 gDNA concentrations.
Table 4. Absolute quantification (copies/µL) and 95% confidence interval (95% CI) of representative mex efflux pump genes presented in various P. aeruginosa ATCC27853 gDNA concentrations.
gDNA Concentration Samples (ng/µL)mexB *mexD *mexY *
Copies/µL95% CICopies/µL95% CICopies/µL95% CI
0.00134.81 ± 9.0032.30–37.3215.52 ± 2.8313.76–17.287.04 ± 1.585.81–8.26
0.00387.43 ± 20.3783.19–91.6638.32 ± 9.0935.55–41.0914.71 ± 1.3213.04–16.38
0.005183.82 ± 12.86176.52–191.1270.50 ± 12.0466.67–74.3333.00 ± 11.5330.39–35.60
0.0501923.07 ± 445.321891.72–1954.421721.94 ± 79.831689.22–1754.65442.64 ± 198.97431.44–453.83
0.5007106.50 ± 44.176821.53–7391.474820.07 ± 919.774698.12–4942.022086.37 ± 144.302050.90–2121.83
1.25010,184.83 ± 782.638901.54–11,468.117729.60 ± 640.497350.85–8108.354117.87 ± 643.554031.39–4204.35
2.50010,388.27 ± 597.329092.85–11,683.689121.83 ± 1298.648300.86–9942.795626.67 ± 733.425465.75–5787.59
NTC0.04 ± 0.03−0.02–0.090.40 ± 0.080.085–0.720.30 ± 0.040.06–0.53
* Note: R2 values between the gDNA concentrations and the absolute quantification of mexB, mexD, and mexY were 0.78 (p = 0.0035), 0.87 (p = 0.0007), and 0.95 (p < 0.0001), respectively.
Table 5. The cut-off values of the effluxR detection assay with mdPCR using ROC analysis and Youden’s index.
Table 5. The cut-off values of the effluxR detection assay with mdPCR using ROC analysis and Youden’s index.
Cut-Off Values of
the Copy Number of Genes (µg/mL)
SensitivitySpecificity1—SpecificityYouden’s Index (J)
−0.9601.0000.0001.0000.000
0.1701.0000.3330.6670.333
0.3501.0000.6670.3330.667
3.7201.0001.0000.0001.000
10.8750.9521.0000.0000.952
15.1150.9051.0000.0000.905
24.2600.8571.0000.0000.857
33.9050.8101.0000.0000.810
36.5650.7621.0000.0000.762
54.4100.7141.0000.0000.714
78.9650.6671.0000.0000.667
135.6250.6191.0000.0000.619
313.2300.5711.0000.0000.571
1082.2900.5241.0000.0000.524
1822.5050.4761.0000.0000.476
2004.7200.4291.0000.0000.429
3102.1200.3811.0000.0000.381
4468.9700.3331.0000.0000.333
5223.3700.2861.0000.0000.286
6366.5850.2381.0000.0000.238
7418.0500.1901.0000.0000.190
8425.7150.1431.0000.0000.143
9653.3300.0951.0000.0000.095
10,286.5500.0481.0000.0000.048
10,389.2700.0001.0000.0000.000
Table 6. The effluxR detection assay with mdPCR detected the 69 positive samples from 84 blinded bacterial reference and clinical isolate strains. No positive signal for mex genes was detected in the 15 negative samples.
Table 6. The effluxR detection assay with mdPCR detected the 69 positive samples from 84 blinded bacterial reference and clinical isolate strains. No positive signal for mex genes was detected in the 15 negative samples.
Sample No.Bacterial SpeciesPresent of Mex Genes Result of effluxR
Detection Assay
mexBmexDmexY
1P. aeruginosa+++Positive for three genes
2P. aeruginosa+++Positive for three genes
3E. coli---Negative for three genes
4P. aeruginosa+++Positive for three genes
5P. aeruginosa+++Positive for three genes
6P. aeruginosa+++Positive for three genes
7S. aureus---Negative for three genes
8E. cloacae---Negative for three genes
9P. aeruginosa+++Positive for three genes
10P. aeruginosa+++Positive for three genes
11P. aeruginosa+++Positive for three genes
12P. aeruginosa+++Positive for three genes
13E. cloacae---Negative for three genes
14P. aeruginosa+++Positive for three genes
15P. aeruginosa+++Positive for three genes
16P. aeruginosa+++Positive for three genes
17P. aeruginosa+++Positive for three genes
18P. aeruginosa+++Positive for three genes
19P. aeruginosa+++Positive for three genes
20K. pneumoniae---Negative for three genes
21P. aeruginosa+++Positive for three genes
22P. aeruginosa+++Positive for three genes
23P. aeruginosa+++Positive for three genes
24P. aeruginosa+++Positive for three genes
25P. aeruginosa+++Positive for three genes
26P. aeruginosa+++Positive for three genes
27P. aeruginosa+++Positive for three genes
28S. aureus---Negative for three genes
29P. aeruginosa+++Positive for three genes
30P. aeruginosa+++Positive for three genes
31S. aureus---Negative for three genes
32P. aeruginosa+++Positive for three genes
33P. aeruginosa+++Positive for three genes
34P. aeruginosa+++Positive for three genes
35E. coli---Negative for three genes
36P. aeruginosa+++Positive for three genes
37P. aeruginosa+++Positive for three genes
38P. aeruginosa+++Positive for three genes
39P. aeruginosa+++Positive for three genes
40K. pneumoniae---Negative for three genes
41P. aeruginosa+++Positive for three genes
42P. aeruginosa+++Positive for three genes
43P. aeruginosa+++Positive for three genes
44P. aeruginosa+++Positive for three genes
45E. coli---Negative for three genes
46K. pneumoniae---Negative for three genes
47P. aeruginosa+++Positive for three genes
48P. aeruginosa+++Positive for three genes
49P. aeruginosa+++Positive for three genes
50P. aeruginosa+++Positive for three genes
51P. aeruginosa+++Positive for three genes
52P. aeruginosa+++Positive for three genes
53P. aeruginosa+++Positive for three genes
54P. aeruginosa+++Positive for three genes
55P. aeruginosa+++Positive for three genes
56P. aeruginosa+++Positive for three genes
57P. aeruginosa+++Positive for three genes
58S. aureus---Negative for three genes
59P. aeruginosa+++Positive for three genes
60P. aeruginosa+++Positive for three genes
61P. aeruginosa+++Positive for three genes
62P. aeruginosa+++Positive for three genes
63P. aeruginosa+++Positive for three genes
64P. aeruginosa+++Positive for three genes
65P. aeruginosa+++Positive for three genes
66P. aeruginosa+++Positive for three genes
67P. aeruginosa+++Positive for three genes
68E. coli---Negative for three genes
69P. aeruginosa+++Positive for three genes
70P. aeruginosa+++Positive for three genes
71P. aeruginosa+++Positive for three genes
72P. aeruginosa+++Positive for three genes
73P. aeruginosa+++Positive for three genes
74K. pneumoniae---Negative for three genes
75P. aeruginosa+++Positive for three genes
76P. aeruginosa+++Positive for three genes
77K. pneumoniae---Negative for three genes
78P. aeruginosa+++Positive for three genes
79P. aeruginosa+++Positive for three genes
80P. aeruginosa+++Positive for three genes
81P. aeruginosa+++Positive for three genes
82P. aeruginosa+++Positive for three genes
83P. aeruginosa+++Positive for three genes
84P. aeruginosa+++Positive for three genes
Total696969
Percentage100100100
Note: symbol (+) is a present gene and (-) is an absent gene.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rattanachak, N.; Weawsiangsang, S.; Baldock, R.A.; Jaifoo, T.; Jongjitvimol, T.; Jongjitwimol, J. A Novel and Quantitative Detection Assay (effluxR) for Identifying Efflux-Associated Resistance Genes Using Multiplex Digital PCR in Clinical Isolates of Pseudomonas aeruginosa. Methods Protoc. 2023, 6, 96. https://doi.org/10.3390/mps6050096

AMA Style

Rattanachak N, Weawsiangsang S, Baldock RA, Jaifoo T, Jongjitvimol T, Jongjitwimol J. A Novel and Quantitative Detection Assay (effluxR) for Identifying Efflux-Associated Resistance Genes Using Multiplex Digital PCR in Clinical Isolates of Pseudomonas aeruginosa. Methods and Protocols. 2023; 6(5):96. https://doi.org/10.3390/mps6050096

Chicago/Turabian Style

Rattanachak, Nontaporn, Sattaporn Weawsiangsang, Robert A. Baldock, Theerasak Jaifoo, Touchkanin Jongjitvimol, and Jirapas Jongjitwimol. 2023. "A Novel and Quantitative Detection Assay (effluxR) for Identifying Efflux-Associated Resistance Genes Using Multiplex Digital PCR in Clinical Isolates of Pseudomonas aeruginosa" Methods and Protocols 6, no. 5: 96. https://doi.org/10.3390/mps6050096

Article Metrics

Back to TopTop